Fig. 5. (A) In vivo MR and (B) CT imaging of nude mice bearing Hela tumors at different time points after intravenous injection of SN38&ICG/Gd&Yb-LDH. (C) In vivo fluorescence imaging and drug bio-distribution for nude mice bearing Hela tumors at different time points after intravenous injection of PBS, SN38&ICG/Gd&Yb-LDH and SN38&ICG, respectively, together with ex vivo imaging of ICG in the tumour and five different organs collected from mice sacrificed at 24 h.
